2. Immunology/Inflammation NF-κB
  3. NOD-like Receptor (NLR) Interleukin Related NF-κB
  4. NLRP3-IN-75

NLRP3-IN-75 is an orally active NLRP3 inhibitor. NLRP3-IN-75 suppresses IL-1β secretion (IC50 = 23 nM). NLRP3-IN-75 selectively inhibits NLRP3 activation by disrupting inflammasome assembly without affecting NLRC4 or AIM2 inflammasomes. NLRP3-IN-75 exhibits superior efficacy in acute peritonitis, diabetic kidney disease and IBD models.

For research use only. We do not sell to patients.

NLRP3-IN-75 Chemical Structure

NLRP3-IN-75 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

NLRP3-IN-75 Related Antibodies

Top Publications Citing Use of Products

View All NOD-like Receptor (NLR) Isoform Specific Products:

View All Isoforms
NLRP3 NLRP1 NOD1 NOD2

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

NLRP3-IN-75 is an orally active NLRP3 inhibitor. NLRP3-IN-75 suppresses IL-1β secretion (IC50 = 23 nM). NLRP3-IN-75 selectively inhibits NLRP3 activation by disrupting inflammasome assembly without affecting NLRC4 or AIM2 inflammasomes. NLRP3-IN-75 exhibits superior efficacy in acute peritonitis, diabetic kidney disease and IBD models[1].

IC50 & Target

IL-1β

23 nM (IC50)

In Vitro

NLRP3-IN-75 (Compound 15) (0.03-100 μM, 30 min) significantly inhibits IL-1β release in LPS- and ATP-stimulated BMDM cells (IC50 = 0.106 μM) and THP-1 cells (IC50 = 23 nM)[1].
NLRP3-IN-75 (10 μM, 4 h) shows selectivity for NLRP3 inflammasome by maintaining IL-1β secretion in the NLRC4 or AIM2 inflammasome pathways in flagellin-transfected BMDM cells[1].
NLRP3-IN-75 (10 μM, 4 h) does not affect the initiation phase of NLRP3 inflammation activation as TNF-α and IL-6 production maintains[1].
NLRP3-IN-75 (10 μM, 4 h) obstructs the interaction between NLRP3 and ASC induced by LPS and ATP in BMDM cells by impeding NLRP3 inflammasome assembly[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

NLRP3-IN-75 Related Antibodies
Parmacokinetics[1]
Species Dose SampleTime Route Indicator value
Mice 20 mg/kg 1 h p.o. AUC0-t 57916 ng·h/mL
Mice 5 mg/kg 1 h i.v. AUC0-t 14525 ng·h/mL
Mice 20 mg/kg 1 h p.o. F 99.6 %
Mice 5 mg/kg 1 h i.v. T1/2 3.63 hr
Mice 20 mg/kg 1 h p.o. T1/2 2.70 hr
Mice 20 mg/kg 1 h p.o. Tmax 0.33 hr
In Vivo

NLRP3-IN-75 (20 mg/kg, p.o., a single dose) ameliorates LPS- and ATP-induced acute peritonitis in mice models[1].
NLRP3-IN-75 (20 mg/kg, p.o., 6 weeks) mitigates HFD- and STZ-induced DKD in mice by targeting the NLRP3 inflammasome [1].
NLRP3-IN-75 (20 mg/kg, p.o., a single dose) shows low potential for cardiovascular or pulmonary toxicity in mice[1].
NLRP3-IN-75 (0.2-5 mg/kg, p.o., 10 days) ameliorates the DSS (HY-116282C)-induced inflammatory bowel disease in mice models[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: LPS (HY-D1056) (15 mg/kg, i.p.)- and ATP (1 mM/kg, i.p.)-induced acute peritonitis mice (6-8 weeks old, male C57BL/6J)[1]
Dosage: 1 mg/kg, 20 mg/kg
Administration: Oral gavage (p.o.)
Result: Achieved 100% survival rate in LPS-induced followed by ATP-induced acute peritonitis mice models.
Suppressed serum IL-1β level in peritonitis mice models 12 h post-ATP administration, and presented better effect with increasing dose.
Animal Model: Male C57BL/6J HFD (4 weeks)- and STZ (HY-13753) (50 mg/kg, i.p., 5 days)-induced diabetic kidney disease (DKD) mice (n = 5-6, 20-22 g)[1]
Dosage: 20 mg/kg, 6 weeks
Administration: Oral gavage (p.o.), 6 weeks; administered after STZ and HFD feeding
Result: Significantly reduced the elevated urine albumin-to-creatinine ratio (UACR) caused by the HFD- and STZ-induced DKD mice models.
Ameliorated the thickening of the glomerular and tubular basement membranes in DKD models.
Decreased inflammatory cytokine IL-1β but no effect on TNF-α level[1].
Reduced macrophage infiltration.
Disrupted the NLRP3-ASC interaction.
Reduced LDL-C levels without affecting HDL-C levels.
Animal Model: 2% (w/v) DSS (HY-116282C) (7 days) in distilled water-induced colitis mice (Male C57BL/6J, n = 5-10, 20-22 g)[1]
Dosage: 0.2 or 5 mg/kg
Administration: Oral gavage (p.o.) , 9 days (day 1-day 10)
Result: Attenuated weight loss in DSS-induced acute colitis mice models.
Reduced fecal bleeding and decreased disease activity index (DAI) scores.
Ameliorated pathological features such as disruption of mucosal barrier, crypt necrosis, substantial depletion of the mucosal barrier, crypt necrosis, substantial depletion of goblet cells, and pronounced infiltration of inflammatory cells.
Inhibited colonic IL-1β without affecting TNF-α level.
Molecular Weight

406.54

Formula

C20H30N4O3S
SMILES

O=C(NC1=C2CCCC2=CC3=C1CCC3)NS(N(C4CCN(CC4)C)C)(=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

NLRP3-IN-75 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

NLRP3-IN-75NOD-like Receptor (NLR)Interleukin RelatedNF-κBILNuclear factor-κBNuclear factor-kappaBInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
NLRP3-IN-75
Cat. No.:
HY-170233
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.